WallStreetZenWallStreetZen

NASDAQ: PRPO
Precipio Inc Stock

Overview
EarningsRevenueDividendOwnership
$5.88+0.37 (+6.72%)
Updated Apr 17, 2025
PRPO Price
$5.88
Fair Value Price
N/A
Market Cap
$8.85M
52 Week Low
$3.90
52 Week High
$10.74
P/E
-2.01x
P/B
0.73x
P/S
0.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.53M
Earnings
-$4.29M
Gross Margin
40.8%
Operating Margin
-22.75%
Profit Margin
-23.1%
Debt to Equity
0.41
Operating Cash Flow
$439k
Beta
0.58
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

PRPO Overview

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PRPO's potential to beat the market

View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Diagnostic & Research

Industry Rating
B
PRPO
RankedUnranked of 45

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Illumina (ILMN)
$71.20A
Qiagen Nv (QGEN)
$40.71B
Mettler Toledo International (MTD)
$1,004.96B
View Top Diagnostic & Research Stocks

Be the first to know about important PRPO news, forecast changes, insider trades & much more!

PRPO News

Overview

Due Diligence Score

–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRPO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PRPO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRPO is good value based on its book value relative to its share price (0.73x), compared to the US Diagnostics & Research industry average (3.26x)
P/B vs Industry Valuation
PRPO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRPO due diligence checks available for Premium users.

Valuation

PRPO price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-2.01x
Industry
36.04x
Market
27.98x

PRPO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.73x
Industry
3.26x
PRPO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PRPO's financial health

Profit margin

Revenue
$5.5M
Net Income
-$365.0k
Profit Margin
-6.7%
PRPO's Earnings (EBIT) of -$4.22M... subscribe to Premium to read more.
Interest Coverage Financials
PRPO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$17.0M
Liabilities
$4.9M
Debt to equity
0.41
PRPO's short-term liabilities ($4.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRPO's short-term assets ($3.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRPO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PRPO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$565.0k
Investing
-$44.0k
Financing
-$185.0k
PRPO's operating cash flow ($439.00k)... subscribe to Premium to read more.
Debt Coverage Financials

PRPO vs Diagnostic & Research Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PRPO–$8.85M+6.72%-2.01x0.73x
BIAF–$9.40M+9.57%-0.69x3.61x
MMA–$9.56M-6.06%-0.66x3.74x
MDXH–$7.92M+3.56%-0.14x0.53x
MYNZC$7.47M+0.63%-0.14x1.24x
View Top Diagnostic & Research Stocks

Precipio Stock FAQ

What is Precipio's quote symbol?

(NASDAQ: PRPO) Precipio trades on the NASDAQ under the ticker symbol PRPO. Precipio stock quotes can also be displayed as NASDAQ: PRPO.

If you're new to stock investing, here's how to buy Precipio stock.

What is the 52 week high and low for Precipio (NASDAQ: PRPO)?

(NASDAQ: PRPO) Precipio's 52-week high was $10.74, and its 52-week low was $3.90. It is currently -45.26% from its 52-week high and 50.77% from its 52-week low.

How much is Precipio stock worth today?

(NASDAQ: PRPO) Precipio currently has 1,504,312 outstanding shares. With Precipio stock trading at $5.88 per share, the total value of Precipio stock (market capitalization) is $8.85M.

Precipio stock was originally listed at a price of $2,591,998.70 in Jul 18, 2000. If you had invested in Precipio stock at $2,591,998.70, your return over the last 24 years would have been -100%, for an annualized return of -41.81% (not including any dividends or dividend reinvestments).

How much is Precipio's stock price per share?

(NASDAQ: PRPO) Precipio stock price per share is $5.88 today (as of Apr 17, 2025).

What is Precipio's Market Cap?

(NASDAQ: PRPO) Precipio's market cap is $8.85M, as of Apr 22, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Precipio's market cap is calculated by multiplying PRPO's current stock price of $5.88 by PRPO's total outstanding shares of 1,504,312.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.